A first patient is treated in Pittsburgh, Pennsylvania as part of the new clinical trial sponsored by Hemerion. The study (HTX-GBM-01) is designed to confirm the safety and feasibility of the Pentalafen® / Heliance® combination therapy in the treatment of glioblastoma : a first in the USA.
Read the press release
